RCM
IONS icon

Riverhead Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Riverhead Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9,650
Closed -$620K – 1521
2019
Q2 		$620K Buy
9,650
+8,250
+589% +$583K 0.02% 646
2019
Q1 		$114K Buy
+1,400
New +$90.3K ﹤0.01% 1300

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Riverhead Capital Management's IONS Position: Q3 2019 in Review

Riverhead Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2019, closing a stake of 9,650 shares — an estimated $620K sold.

Riverhead Capital Management first reported a position in IONS in Q1 2019 and held it in 2 quarters. The position peaked at $620K in Q2 2019. 370 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

  • Riverhead Capital Management reported no remaining Ionis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 9,650 Ionis Pharmaceuticals shares in Q3 2019, an estimated $620K.
  • Riverhead Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Riverhead Capital Management's Ionis Pharmaceuticals position peaked at $620K in Q2 2019.
  • 370 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.